Relmada Therapeutics is a reputable clinical-stage firm that specializes in developing novel therapies for the treatment of chronic pain. The company has announced that it has filed a motion, which is part of the lawsuit it filed in the Nevada District Court to amend its complaint against Laidlaw & Company (UK) Ltd. Remalda’s amendment includes a new lawful claim against Laidlaw & Company for breaching the fiduciary agreement when it disclosed confidential information while serving as Relmada’s investment banker.
Relmada Therapeutics also seeks monetary compensation for damages arising from fees and costs incurred while responding to Laidlaw’s false misleading proxy materials in December 2015. As a result of the false misleading proxy materials, Nevada court had earlier issued an interim restraining order and an injunction against Laidlaw and its principals, Matthew Eitner and James Ahern. Relmada’s Board believes Laidlaw must compensate the company for damages it suffered. Relmada Therapeutics is planning to mail its shareholders to inform them of this action, which aims at protecting their interests.
About Laidlaw & Company
Laidlaw & Company is an excellent investment banking and brokerage firm that offers financial advisory to private and public institutions. Currently, the company operates under the Sands Brothers International Ltd. Having served as Relmada’s investment banker and financial advisor, Laidlaw & Company still offers excellent services; however, it is tasked with reinstating its reputation to the previous status. Even with the recent legal dispute with Relmada, Laidlaw & Company’s principals, Matthew Eitner and James Ahern, commits to providing cutting-edge services that exceed customer needs.